About Nventa Biopharmaceuticals Corporation:
Nventa is developing innovative therapeutics incorporating our proprietary CoVal(TM) fusion technology for the treatment of viral infections and cancers, with a focus on diseases caused by the human papillomavirus (HPV); and a Toll- like Receptor 3 (TLR3) agonist for use as a vaccine adjuvant and as an immunotherapeutic for viral infections and cancer. The company is publicly traded on the Toronto Stock Exchange under the symbol "NVN". For more information about Nventa Biopharmaceuticals Corporation, please visit the company's website located at http://www.nventacorp.com.
The audit committee of the company has reviewed and approved of the contents of this press release. Summary financial statements are attached below. The full financial statements and MD&A for the three and nine months ended September 30, 2008 can be found on SEDAR at http://www.sedar.com.
This press release contains statements which may constitute forward-
looking information under applicable Canadian securities legislation or
forward-looking statements within the meaning of the United States Private
Securities Litigation Reform Act of 1995. Such forward-looking statements
or information may include financial and other projections as well as
statements regarding the company's future plans, objectives, performance,
revenues, growth, profits, operating expenses or the company's underlying
assumptions. The words "may", "would", "could", "will", "likely", "expect,"
"anticipate," "intend", "plan", "forecast", "project", "estimate" and
"believe" or other similar words and phrases may identify forward-looking
statements or information. Persons reading this press release are cautioned
that such statements or information are only expectations, and that the
company's actual future results or perform
|SOURCE Nventa Biopharmaceuticals Corporation|
Copyright©2008 PR Newswire.
All rights reserved